275 related articles for article (PubMed ID: 19387454)
1. Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Al-Ameri H; Kloner RA
Int J Impot Res; 2009; 21(3):149-57. PubMed ID: 19387454
[TBL] [Abstract][Full Text] [Related]
2. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
4. Erectile dysfunction in heart failure patients: a critical reappraisal.
Alberti L; Torlasco C; Lauretta L; Loffi M; Maranta F; Salonia A; Margonato A; Montorsi F; Fragasso G
Andrology; 2013 Mar; 1(2):177-91. PubMed ID: 23339018
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
6. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
[TBL] [Abstract][Full Text] [Related]
7. Erectile dysfunction in the cardiac patient.
Kloner RA
Curr Urol Rep; 2003 Dec; 4(6):466-71. PubMed ID: 14622500
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for erectile dysfunction in patients with diabetes mellitus.
Basu A; Ryder RE
Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
10. [From the Cochrane Library: Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men].
Hamerlynck JV; Middeldorp S; Hooft L
Ned Tijdschr Geneeskd; 2007 Sep; 151(38):2101-4. PubMed ID: 17948826
[TBL] [Abstract][Full Text] [Related]
11. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.
Kloner RA; Stanek E; Crowe CL; Singhal M; Pepe RS; Bradsher J; Rosen RC
J Sex Med; 2023 Jan; 20(1):38-48. PubMed ID: 36897243
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
13. Novel phosphodiesterase-5 inhibitors: current indications and future directions.
Sharma R
Indian J Med Sci; 2007 Dec; 61(12):667-79. PubMed ID: 18174638
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of vardenafil in men with erectile dysfunction and depression].
Hu L
Zhonghua Nan Ke Xue; 2004 Nov; 10(11):876-9. PubMed ID: 15595695
[TBL] [Abstract][Full Text] [Related]
15. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S
Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012
[TBL] [Abstract][Full Text] [Related]
16. Heart Failure and Erectile Dysfunction: a Review of the Current Evidence and Clinical Implications.
Carella MC; Forleo C; Stanca A; Carulli E; Basile P; Carbonara U; Amati F; Mushtaq S; Baggiano A; Pontone G; Ciccone MM; Guaricci AI
Curr Heart Fail Rep; 2023 Dec; 20(6):530-541. PubMed ID: 37962749
[TBL] [Abstract][Full Text] [Related]
17. ERECTILE DYSFUNCTION AS A PREDICTOR OF CARDIOVASCULAR DISEASE.
Janjgava S; Doliashvili T
Georgian Med News; 2016 Dec; (261):36-41. PubMed ID: 28132040
[TBL] [Abstract][Full Text] [Related]
18. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
Laties AM
Drug Saf; 2009; 32(1):1-18. PubMed ID: 19132801
[TBL] [Abstract][Full Text] [Related]
19. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
20. [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
Porst H
Urologe A; 2004 Jul; 43(7):820-8. PubMed ID: 15197447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
